Pamidronate attenuates diastolic dysfunction induced by myocardial infarction associated with changes in geometric...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Cardiac Physiology

Background:

• Myocardial infarction (MI) leads to adverse ventricular remodeling and impaired cardiac function.
• Bisphosphonates, like pamidronate, are primarily used for bone diseases but may have cardioprotective effects.
• Understanding pamidronate's impact on post-MI cardiac remodeling is crucial for potential therapeutic applications.

Purpose of the Study:

• To investigate the effects of pamidronate on ventricular remodeling and function following myocardial infarction in a rat model.
• To assess whether pamidronate can mitigate the negative consequences of MI on cardiac structure and performance.

Main Methods:

• Male Wistar rats were divided into four groups: sham surgery with saline, sham surgery with pamidronate, MI with saline, and MI with pamidronate.
• Pamidronate (3 mg/kg) or saline was administered weekly via subcutaneous injection for three months post-surgery/MI.
• Cardiac function, ventricular dimensions, myocyte hypertrophy, collagen content, and calcium handling proteins were evaluated.

Main Results:

• Myocardial infarction induced left ventricular enlargement and worsened diastolic and systolic function compared to sham groups.
• Pamidronate treatment in MI rats showed a lower E/A ratio and reduced left ventricular posterior and relative wall thickness compared to the MI group.
• No significant interaction was observed between pamidronate and MI on systolic function, myocyte hypertrophy, collagen content, or calcium handling proteins.

Conclusions:

• Pamidronate administration attenuates diastolic dysfunction in the context of myocardial infarction.
• Pamidronate does not appear to improve systolic function or alter key structural and molecular markers of remodeling post-MI in this model.